Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | RGS12 | O14924 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30354606 | 1.00 | KDM4E (0.50) | KDM4EHPGDHSD17B10MAPTGAA | |
| SCHEMBL1100571 | 0.85 | HPGD (0.50) | KDM4EHPGDHSD17B10MAPTGAA | |
| SCHEMBL5239543 | 0.85 | POLB (0.44) | KDM4EMAPTGAATDP1POLB | |
| SCHEMBL849433 | 0.83 | CA2 (0.47) | KDM4EMAPTGAATDP1POLB | |
| SCHEMBL969589 | 0.82 | HPGD (0.55) | KDM4EHPGDHSD17B10MAPTGAA | |
| SCHEMBL10616039 | 0.82 | KDM4E (0.55) | KDM4EHPGDHSD17B10MAPTGAA | |
| SCHEMBL4814385 | 0.81 | FFAR4 (0.59) | THRB | |
| SCHEMBL2597962 | 0.81 | KDM4E (0.50) | KDM4EHPGDHSD17B10MAPTGAA | |
| SCHEMBL14712149 | 0.80 | ALDH1A1 (0.53) | KDM4EHPGDMAPTGAATSHR | |
| Hydrochloric Acid SCHEMBL2530255 | 0.80 | HPGD (0.53) | KDM4EHPGDHSD17B10MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100358873-C | Slfonyl urea compounds and their production method and use | UNIV NANKAI (CN) | 2008-01-02 | — | — | CN | claimed |
| CN-1569844-A | Slfonyl urea compounds and their production method and use | UNIV NANKAI (CN) | 2005-01-26 | — | — | CN | claimed |
| EP-4615573-A1 | GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | Eli Lilly and Company (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250002482-A1 | GLUCAGON-LIKE PEPTIDE1 RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2025-01-02 | — | — | US | disclosed |
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | CALICO LIFE SCIENCES LLC (US) | 2024-12-26 | — | — | US | disclosed |
| US-12145924-B2 | Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds | ELI LILLY AND COMPANY (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240245673-A1 | Papain-like protease (PLpro) inhibitors | PFIZER INC. (US) | 2024-07-25 | — | — | US | disclosed |
| WO-2024130341-A1 | BENZIMIDAZOLE DERIVATIVES FOR THE MODULATION OF STING | Aculeus Therapeutics Pty Ltd (AU) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024121779-A1 | PAPAIN-LIKE PROTEASE (PLPRO) INHIBITORS | PFIZER INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024102625-A1 | GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-4359409-A1 | DEGRADER COMPOUNDS AND USES THEREOF | Calico Life Sciences LLC (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2013025733-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2011-09-29 | — | — | US | disclosed |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2011-09-29 | — | — | US | disclosed |
| WO-2010101849-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2010-09-10 | — | — | WO | disclosed |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-03 | — | — | US | disclosed |
| CN-100358873-C | Slfonyl urea compounds and their production method and use | UNIV NANKAI (CN) | 2008-01-02 | — | — | CN | disclosed |
| EP-1806332-A1 | BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS | Daiichi Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
| CN-1569844-A | Slfonyl urea compounds and their production method and use | UNIV NANKAI (CN) | 2005-01-26 | — | — | CN | disclosed |
| WO-1998050346-A2 | ACETAMIDE AND UREA DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002482-A1 | GLUCAGON-LIKE PEPTIDE1 RECEPTOR AGONISTS | GLP1R, GCGR, GIPR | KDM4E 2784/4885HPGD 3190/4885HSD17B10 2644/4885 |
| US-20240245673-A1 | Papain-like protease (PLpro) inhibitors | PREP, PEPD, ACE | KDM4E 4373/4885HPGD 893/4885HSD17B10 1720/4885 |
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | PTPN1, PTPN2, PTPN5 | KDM4E 725/4885HPGD 2895/4885HSD17B10 1184/4885 |
| US-12145924-B2 | Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds | LPAR1, LPAR2, LPAR5 | KDM4E 3048/4885HPGD 2443/4885HSD17B10 1523/4885 |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, CTNNB1, WNT3A | KDM4E 1885/4885HPGD 2439/4885HSD17B10 1229/4885 |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | NR1H2, NR1H3, NCOR2 | KDM4E 1970/4885HPGD 3933/4885HSD17B10 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.